Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=17938483&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Role of chelates in treatment of cancer Tripathi L; Kumar P; Singhai AKIndian J Cancer 2007[Apr]; 44 (2): 62-71Chelates are used in cancer as cytotoxic agent, as radioactive agent in imaging studies and in radioimmunotherapy. Various chelates based on ruthenium, copper, zinc organocobalt, gold, platinum, palladium, cobalt, nickel and iron are reported as cytotoxic agent. Monoclonal antibodies labeled with radioactive metals such as yttrium-90, indium-111 and iodine-131 are used in radioimmunotherapy. This review is an attempt to compile the use of chelates as cytotoxic drugs and in radioimmunotherapy.|Animals[MESH]|Antibodies, Monoclonal/therapeutic use[MESH]|Antineoplastic Agents/therapeutic use[MESH]|Cell Growth Processes/drug effects/radiation effects[MESH]|Chelating Agents/therapeutic use[MESH]|Chelation Therapy/*trends[MESH]|Cytotoxins/therapeutic use[MESH]|Drug Therapy/*trends[MESH]|Humans[MESH]|Mice[MESH]|Neoplasms/*drug therapy/pathology/*radiotherapy[MESH]|Radioimmunotherapy/*trends[MESH]|Radioisotopes/therapeutic use[MESH]|Rats[MESH]|Treatment Outcome[MESH] |
